Biomarkers May Hold Therapeutic Potential for Multiple… : Oncology Times
An abstract is unavailable.
An abstract is unavailable.
Advancements in hematopathology based on molecular and genetic information are rapidly evolving, making it challenging to keep up with the latest developments and their implications…
Abstract. RAF inhibitors have transformed treatment for BRAF V600-mutant cancer patients, but clinical benefit is limited by adaptive induction of ERK signaling, genetic alterations that…
Christian Marth, MD, PhD, discusses efficacy and safety findings from the phase 3 LEAP-001 trial in advanced/recurrent endometrial cancer.
Arlene O. Siefker-Radtke, MD, discusses toxicities associated with enfortumab vedotin plus pembrolizumab in patients with bladder cancer.
Abstract. Tumor cells rewire their metabolism to fulfill the demands of highly proliferative cells. This changes cellular metabolism to adapt to fuel and oxygen availability…
An Overview of MOA, Clinical Data, and Dosing Considerations
An abstract is unavailable.
Early research suggests setanaxib combined with pembrolizumab may be a promising treatment for patients with squamous cell carcinoma of the head and neck.
The United States Preventive Services Task Force (USPSTF) issued an update to its guidelines for breast cancer screenings, but experts at Moffitt Cancer Center say…
The OncoAlert Newsletter is now out for June 23-29, 2023